Table 2.
Incidence of triple combination therapy and time to triple combination therapy in the propensity score matched population.
| Baseline Characteristics | All (n = 4888) | LAMA (n = 2444) | ICS/LABA (n = 2444) | p Value |
|---|---|---|---|---|
| Incidence rate per 1000 person-years | 106.8 | 81.0 | 139.8 | <0.001 |
| Patients with event | 901 | 383 | 518 | 0.09 |
| Median time to event | 227 | 281 | 207 | 0.03 |
| Age (years) | <0.001 | |||
| 55 to <65 | 435.3 ± 501.6 | 460.0 ± 558.9 | 415.0 ± 449.9 | |
| 65 to <75 | 397.96 ± 461.1 | 479.63 ± 532.2 | 338.8 ± 392.6 | |
| 75+ | 349.41 ± 406.8 | 382.67 ± 381.8 | 327.1 ± 422.7 | |
| Sex | ||||
| Male | 406.0 ± 464.1 | 473.9 ± 514.8 | 358.2 ± 418.9 | <0.001 |
| Female | 353.4 ± 450.0 | 349.1 ± 482.4 | 357.6 ± 420.3 | 0.001 |
| History of COPD exacerbation | ||||
| None | 395.9 ± 458.2 | 444.7 ± 503.6 | 360.0 ± 418.9 | <0.001 |
| 1 moderate | 416.3 ± 502.4 | 513.7 ± 566.9 | 347.61 ± 443.5 | <0.0001 |
| ≥ 2 moderate OR ≥ 1 severe | 391.0 ± 452.1 | 433.9 ± 505.9 | 357.6 ± 405.1 | 0.005 |
| History of asthma | ||||
| No | 395.6 ± 457.4 | 461.6 ± 497.9 | 351.7 ± 423.6 | <0.001 |
| Yes | 399.1 ± 466.8 | 441.0 ± 522.0 | 364.8 ± 414.3 | <0.001 |
Data are expressed as mean ± standard deviation or n (%). LAMA, long-acting muscarinic antagonist; ICS/LABA, inhaled corticosteroid plus long-acting beta-2 agonist; COPD, chronic obstructive pulmonary disease.